Summary by Futu AI
Aditxt, Inc. (Aditxt) has filed an Amendment No. 2 to its Form 8-K/A with the SEC, providing additional financial information related to its merger with Evofem Biosciences, Inc. (Evofem). The amendment includes historical financial statements for Evofem for the six months ended June 30, 2024, and pro forma financial information for the same period. The merger, initially reported on December 11, 2023, involves Aditxt's wholly owned subsidiary, Merger Sub, merging with Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt. The merger is part of Aditxt's strategic expansion and was preceded by an Original Agreement filed on December 12, 2023. The merger's completion is pending, with financial statements and pro forma information required by Form 8-K now included in the amendment. This information is intended for informational purposes and does not represent actual or projected post-merger operations.